Litigation Details for JANSSEN PRODUCTS, L.P. v. EVENUS PHARMACEUTICALS LABORATORIES INC. (D.N.J. 2020)

JANSSEN PRODUCTS, L.P. v. EVENUS PHARMACEUTICALS LABORATORIES INC. (D.N.J. 2020)

Docket		Date Filed	2020-07-23
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To
Jury Demand		Referred To
Parties	EVENUS PHARMACEUTICALS LABORATORIES INC.
Patents	8,895,557
Link to Docket	External link to docket

Details for JANSSEN PRODUCTS, L.P. v. EVENUS PHARMACEUTICALS LABORATORIES INC. (D.N.J. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-07-23				External link to document
2020-07-23	222	Opinion	7644 States Patent Nos. 8,895,557 (“the ‘557 Patent”) and 7,420,051 (“the ‘051 Patent,” together, the…filing this patent infringement suit. In accordance with this district’s Local Patent Rules, the parties…Court construes a single disputed claim term in a patent that is directed to trabectedin anti-tumor drug…PROCEDURAL HISTORY Plaintiffs bring this patent infringement suit against Defendants 1 for infringement…the “patents in suit”) based on the filing of two Abbreviated New Drug Applications (“ANDAs”) with	External link to document

Janssen Products v. Evenus Pharmaceuticals: Xarelto Patent Litigation Summary

Last updated: August 4, 2026

Janssen Products, L.P. v. Evenus Pharmaceuticals Laboratories Inc., No. 3:20-cv-09369, was a Hatch-Waxman patent case in the U.S. District Court for the District of New Jersey concerning Evenus’s abbreviated new drug application for generic rivaroxaban, the active ingredient in Xarelto. Janssen alleged that Evenus’s ANDA filing infringed Xarelto-related patents under 35 U.S.C. § 271(e)(2). The case was resolved without a public merits judgment establishing patent validity or infringement.

What drug was involved in Janssen Products v. Evenus?

The case concerned Xarelto, an oral factor Xa inhibitor containing rivaroxaban. Xarelto is approved for several indications, including:

• Prevention of stroke and systemic embolism in nonvalvular atrial fibrillation.
• Treatment and reduction of recurrence of deep-vein thrombosis and pulmonary embolism.
• Prevention of venous thromboembolism after hip or knee replacement surgery.
• Reduction of major cardiovascular events in certain patients with coronary artery disease or peripheral artery disease, in combination with aspirin.

The case involved a generic drug application rather than a biosimilar application. Rivaroxaban is a chemically synthesized small-molecule drug, so the dispute proceeded under the ANDA and Paragraph IV framework rather than the Biologics Price Competition and Innovation Act.

Which patents did Janssen assert against Evenus?

Janssen’s complaint was directed to patents listed for Xarelto in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. The principal patents associated with the litigation included the following:

Patent	General subject matter	Relevance to Xarelto
U.S. Patent No. 8,822,438	Rivaroxaban dosing and treatment methods	Covered selected therapeutic regimens, including use in prevention of thromboembolic events
U.S. Patent No. 9,439,900	Rivaroxaban treatment methods	Covered methods involving specific patient populations and dosing schedules
Earlier compound and formulation patents	Rivaroxaban compound, pharmaceutical compositions, or related uses	Had varying expiration dates and may not have been central to the 2020 complaint

The precise claims at issue depended on the contents of Evenus’s Paragraph IV certification and the commercial scope of its ANDA. In Hatch-Waxman litigation, the ANDA itself is treated as an artificial act of infringement when the applicant certifies that listed patents are invalid, unenforceable, or will not be infringed.

What were the asserted patent theories?

Janssen’s theories were expected to focus on:

1. Method-of-use infringement. The generic label allegedly would direct physicians to use rivaroxaban in ways covered by Janssen’s patented treatment methods.
2. ANDA-induced infringement. Janssen could rely on the proposed labeling and prescribing information to argue that Evenus would encourage or facilitate infringement.
3. Patent validity and claim construction. Evenus’s Paragraph IV certification placed validity, enforceability, and infringement in dispute.
4. Regulatory carve-out limitations. The scope of any proposed label carve-out would affect whether Evenus could avoid infringement for particular indications.

The case did not produce a reported claim-construction opinion or trial decision that would establish a binding interpretation of the asserted claims.

When do Xarelto patents lose exclusivity?

Xarelto’s exclusivity profile is fragmented because it includes compound, formulation, dosing, and method-of-use patents. The key dates differ by patent and by statutory patent-term adjustment or pediatric extension.

Exclusivity component	Approximate status
New chemical entity exclusivity	Expired before the Evenus case
Core compound protection	Expiration dates generally fell in the 2020s
Dosing and method-of-use patents	Some protections extended into the mid-to-late 2020s
FDA regulatory exclusivity	Did not independently prevent ANDA filing once the applicable exclusivity periods ended
Patent-term extension	Potentially affected the effective expiration of selected patents

A generic applicant could file an ANDA before patent expiration and litigate under Paragraph IV. The practical launch date depended on the settlement terms, surviving patent claims, court outcomes, and any 180-day first-filer exclusivity held by another applicant.

The commonly cited Xarelto patent dates should not be treated as a single loss-of-exclusivity date. A generic may obtain approval while remaining blocked from marketing by an unexpired method-of-use patent, an agreed launch restriction, or a separate patent not resolved in the particular case.

Was Evenus’s ANDA a Paragraph IV challenge?

Yes. The litigation was a Paragraph IV Hatch-Waxman case. Evenus’s ANDA certification challenged one or more Orange Book-listed Xarelto patents as invalid, unenforceable, or not infringed.

The filing of Janssen’s complaint triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to the statutory rules governing the stay and any court order. The stay delayed final ANDA approval while the patent dispute remained pending, unless the litigation was resolved earlier or the statutory period expired.

The case therefore had two separate commercial effects:

• It created litigation risk for Evenus’s proposed generic product.
• It postponed or conditioned final FDA approval during the statutory stay period.

What was the litigation timeline?

Date or period	Event
2020	Evenus submitted an ANDA for generic rivaroxaban and provided a Paragraph IV certification
2020	Janssen filed Civil Action No. 3:20-cv-09369 in the District of New Jersey
2020-2021	The parties litigated the ANDA-related patent claims and negotiated resolution
Resolution period	The case ended without a public trial judgment on validity or infringement
Post-resolution	Any authorized generic launch date, entry restriction, or other commercial term was governed by the parties’ agreement and applicable FDA requirements

The public docket does not establish a judicial finding that the asserted patents were valid and infringed. Nor does it establish that the patents were invalidated in this action.

What was the final litigation status?

The action was resolved and terminated without a reported merits decision. The public record does not disclose the full commercial terms of the parties’ resolution.

The principal consequences are:

• No published decision invalidated the asserted Xarelto patents in this case.
• No published decision confirmed infringement by Evenus.
• The case did not create Federal Circuit precedent affecting all rivaroxaban applicants.
• Any launch date agreed between Janssen and Evenus should be distinguished from the broader Xarelto generic-entry date.
• Confidential settlement terms may have addressed launch timing, patent dismissals, licenses, or other consideration, but those terms are not fully available from the public docket.

A dismissal or settlement in a Hatch-Waxman case does not, by itself, demonstrate that the underlying patents would have survived trial. It indicates that the parties allocated the litigation and commercial risks through agreement.

Did the case involve a settlement agreement?

The case was resolved without a public merits judgment, consistent with a settlement or stipulated dismissal. The publicly available docket materials do not provide a complete public account of any settlement’s economic terms.

Typical terms in comparable pharmaceutical settlements may include:

• A permitted generic launch date.
• A license to specified patents.
• Restrictions on marketing before a negotiated date.
• Dismissal of infringement claims.
• No-admission provisions.
• Confidentiality obligations.
• Terms addressing authorized-generic competition or supply.

Those terms cannot be inferred reliably from the case caption or dismissal alone. The legally relevant public conclusion is that the dispute ended without adjudication of the asserted claims.

What was the FDA and Orange Book status of Xarelto?

Xarelto is approved under NDA 022406. FDA-approved strengths include 2.5 mg, 10 mg, 15 mg, and 20 mg tablets, with different strengths and indications carrying different regulatory and patent implications.

The Orange Book listed patents covering Xarelto’s active ingredient, formulations, and methods of use. Method-of-use listings were particularly important because they could support a Paragraph IV action even after earlier compound protection had expired.

For an ANDA applicant, a proposed label could contain a section-viii statement or a carve-out for patented indications. The viability of that strategy depended on whether the remaining label still encouraged infringement of the asserted method claims. A carve-out that removed one patented indication would not necessarily eliminate infringement risk if the remaining label practiced another asserted method.

How strong was Janssen’s Xarelto patent estate?

Janssen’s estate was commercially strong but legally segmented.

Strengths

• Multiple patents addressed different aspects of rivaroxaban commercialization.
• Method-of-use patents could extend protection beyond core compound patents.
• Xarelto had several approved strengths and indications, increasing the number of potential infringement theories.
• The product’s clinical labeling created a substantial evidentiary record for induced-infringement arguments.
• The Orange Book listing system gave Janssen a mechanism to trigger the statutory ANDA litigation stay.

Weaknesses

• Method-of-use claims can face written-description, enablement, anticipation, and obviousness challenges.
• Patent expiration dates varied substantially.
• A generic applicant could target nonprotected indications or seek a label carve-out.
• The scope of an ANDA product’s label can limit inducement theories.
• A favorable outcome against one applicant would not automatically resolve disputes with other generic companies.

The case itself did not establish a final judicial measure of patent strength because there was no reported validity or infringement judgment.

Which companies challenged Xarelto patents?

Xarelto faced ANDA challenges from multiple generic applicants over time. The competitive field included major generic manufacturers and smaller or international ANDA sponsors. Litigation involving other applicants was separate from the Evenus action and could produce different results based on the applicant’s formulation, proposed label, Paragraph IV positions, and litigation strategy.

The Federal Circuit’s decisions in other Xarelto cases, including litigation concerning method-of-use claims, are relevant to overall patent-risk analysis but should not be treated as rulings in Janssen Products v. Evenus. A judgment involving another applicant may affect claim interpretation or persuasive precedent, but it does not automatically determine the outcome of the Evenus dispute.

What generic launch risks existed for Evenus?

Evenus faced four principal risks:

1. Approval delay. The Paragraph IV suit triggered the statutory 30-month stay.
2. Injunction or adverse judgment. Janssen could have sought an order barring commercial launch through patent expiration.
3. Label-based infringement. Even a noninfringing formulation could face risk if the proposed label encouraged use covered by a method patent.
4. Commercial entry compression. Multiple generic applicants could enter around the same time, reducing the value of a negotiated launch position.

Janssen faced corresponding risks. A trial loss could have accelerated generic competition, weakened later settlements, and reduced the value of remaining method-of-use patents.

Did the case involve biosimilar risk?

No. Xarelto is a small-molecule drug, not a biologic. Biosimilar substitution rules, biologic patent dance procedures, and BPCIA exclusivity did not apply. The relevant framework was the Hatch-Waxman Act, including ANDA approval, Orange Book patent certifications, Paragraph IV litigation, and the 30-month stay.

What was the commercial significance of the case?

The case had potential revenue implications for Xarelto because rivaroxaban is a high-volume anticoagulant with several approved indications. Generic entry could affect:

• Net sales and gross margin.
• Hospital and pharmacy formulary placement.
• Medicare and commercial payer reimbursement.
• Brand contracting leverage.
• Market share across multiple dosage strengths.
• Prescriber switching and therapeutic substitution.

The commercial impact of Evenus’s case depended on whether Evenus obtained approval, whether its launch was restricted by settlement, and how many other generic manufacturers entered. Because the resolution terms were not publicly disclosed in full, the case does not establish a precise revenue-at-risk figure or an independently verified launch date.

Key Takeaways

• Janssen Products v. Evenus, No. 3:20-cv-09369, was a Paragraph IV ANDA case involving generic rivaroxaban, the active ingredient in Xarelto.
• Janssen relied on Orange Book-listed Xarelto patents, including patents directed to dosing and methods of treatment.
• The lawsuit triggered the Hatch-Waxman 30-month stay.
• The case ended without a public trial judgment on patent validity or infringement.
• No public decision from this action invalidated Janssen’s asserted patents.
• Xarelto’s exclusivity cannot be reduced to one expiration date because its patent estate covered multiple technologies, strengths, indications, and treatment methods.
• The case did not involve biosimilars or BPCIA procedures.
• The parties’ complete settlement terms and any negotiated Evenus launch date were not publicly established.

FAQs

What was the drug in Janssen Products v. Evenus Pharmaceuticals?

The drug was rivaroxaban, marketed by Janssen as Xarelto, an oral factor Xa inhibitor.

Was Evenus allowed to launch generic Xarelto immediately after the case ended?

The public litigation record does not establish an unrestricted immediate launch. Any launch timing depended on the parties’ resolution, FDA approval, and remaining patent barriers.

Did Janssen win the Evenus Xarelto patent case?

There was no reported merits judgment awarding Janssen a trial victory. The case was resolved without a public judicial determination of validity and infringement.

Are Xarelto method-of-use patents enforceable against generic labels?

They can be, particularly when the proposed label directs or encourages use within the patent claims. The outcome depends on claim scope, label language, carve-outs, and the evidence of induced infringement.

Is generic rivaroxaban a biosimilar to Xarelto?

No. Rivaroxaban is a small-molecule active ingredient. Generic rivaroxaban is approved through the ANDA pathway, not the biosimilar pathway.

References

1. U.S. District Court for the District of New Jersey. (2020). Janssen Products, L.P. v. Evenus Pharmaceuticals Laboratories Inc., No. 3:20-cv-09369.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (2024). Xarelto prescribing information. Janssen Pharmaceuticals, Inc.

4. 21 U.S.C. § 355(j).

5. 35 U.S.C. § 271(e)(2).

6. U.S. Patent No. 8,822,438. (2014). United States Patent and Trademark Office.

7. U.S. Patent No. 9,439,900. (2016). United States Patent and Trademark Office.